BPC-157: Overview of Published Preclinical Research
Summary of peer-reviewed laboratory findings. For research use only.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a partial sequence of a naturally occurring gastric peptide.
It has been investigated in preclinical models for its involvement in cellular signaling, vascular responses, and tissue-related research contexts.
All findings summarized below originate from non-clinical studies and remain exploratory.
Research Directions Reported in Preclinical Models
Mechanistic Observations (In-Vitro)
Cell culture studies using tendon fibroblasts have reported modulation of growth hormone receptor (GHR) expression
and proliferation-associated markers under specific laboratory conditions.
These observations highlight areas for continued investigation into pathway involvement rather than confirmed functional outcomes.
| Focus | Model | Reported Observation |
|---|---|---|
| GHR expression | Tendon fibroblasts (in vitro) | Changes in mRNA and protein expression under defined conditions. |
| Cell proliferation markers | Fibroblast cultures | Altered expression of proliferation-associated markers in select models. |
Explore BPC-157 for Research
PeptiSearch supplies research-grade BPC-157 with independent third-party testing and published certificates of analysis.
Research Considerations
- All data summarized originate from animal or cell-based studies.
- Reported observations vary by experimental design, species, and exposure parameters.
- Independent replication and additional studies are required to clarify mechanisms.
Sources
- Xu C, et al. Preclinical safety evaluation of body protective compound-157.
Regul Toxicol Pharmacol. 2020;114:104665.
PubMed - Chang CH, et al. Pentadecapeptide BPC-157 and growth hormone receptor expression in tendon fibroblasts.
Molecules. 2014;19:19066–19077.
PMC - He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of BPC-157 in animal models.
Front Pharmacol. 2022;13:1026182.
PMC